BF2.649

DRUG10 trials

Conditions

CataplexyExcessive Daytime SleepinessNarcolepsyObstructive Sleep ApneaObstructive Sleep ApnoeaRenal ImpairmentSchizophreniaSleep Disorders

Phase 1

Pharmacokinetics of BF2.649 in Renal Impairment

CompletedNCT01619033

BioprojetRenal Impairment

Start: 2011-07-31End: 2012-11-30Updated: 2013-04-12

Phase 2

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

CompletedNCT00690274

University of Texas Southwestern Medical CenterSchizophrenia

Start: 2008-06-30End: 2011-10-31Updated: 2019-04-23

Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)

CompletedNCT01620554

BioprojetExcessive Daytime Sleepiness, Obstructive Sleep Apnoea

Start: 2010-10-31End: 2011-12-31Updated: 2012-06-15

Phase 3

Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy

CompletedNCT01067235

BioprojetCataplexy, Excessive Daytime Sleepiness, Narcolepsy

Start: 2009-10-31End: 2010-07-31Updated: 2013-02-11

Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy

CompletedNCT01067222

BioprojetCataplexy, Excessive Daytime Sleepiness, Narcolepsy +1

Start: 2009-05-31End: 2010-12-31Updated: 2012-06-11

BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS

CompletedNCT01071876

BioprojetExcessive Daytime Sleepiness, Obstructive Sleep Apnea

Start: 2011-08-31End: 2014-03-31Updated: 2015-01-21

BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.

CompletedNCT01072968

BioprojetExcessive Daytime Sleepiness, Obstructive Sleep Apnea

Start: 2011-10-31End: 2014-05-31Updated: 2015-01-21

Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)

CompletedNCT01399606

BioprojetCataplexy, Narcolepsy

Start: 2011-05-31End: 2016-09-30Updated: 2017-01-31

Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.

CompletedNCT01638403

BioprojetTreatment of Excessive Daytime Sleepiness in Narcolepsy

Start: 2010-11-30End: 2012-07-31Updated: 2017-01-31

Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)

CompletedNCT01789398

BioprojetNarcolepsy

Start: 2012-09-30End: 2014-08-31Updated: 2015-11-18

2023-11-179 citations

Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials

BMC Psychiatry2022-02-229 citations

Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials

CNS Drugs2021-12-2113 citations

Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials.

2021-11-254 citations

Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial.

2020-10-2649 citations

Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial

American Journal of Respiratory and Critical Care Medicine2020-01-09263 citations

Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test.

2015-07-0144 citations

Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.

2013-10-07227 citations

BF2.649

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers